丹参对缺血性心肌损伤保护的非循环机制

目的 :通过丹参注射液对培养心肌细胞缺血性损伤中的心肌酶、心肌细胞超微结构和心肌细胞凋亡的影响 ,探讨其保护作用和机制。方法 :将培养第4天的心肌细胞随机分为 4组 :正常对照组 (A组 ) ,缺糖缺氧组 (B组 ) ,小剂量丹参组 (C组 ) ,大剂量丹参组 (D组 ) ,实验结束取培养液上清液检测LDH、α -HBDH ,收集细胞分别做透射电镜及细胞凋亡的检测。结果 :LDH、α -HBDHB组明显高于A组 (P <0 .0 1) ,C组、D组分别低于B组 (P <0 .0 5 ) ,而稍高于A组 (P >0 .0 5 ) ,C组、D组间无统计学意义 (P >0 .0 5 ) ;置显微镜下心肌细胞A组完好 ,B组其内有空泡形成 ,颗粒增加 ,甚至有变性坏死 ,C组、D组细胞也有少量空泡形成 ,细胞核尚正常 ;电镜下心肌细胞A组线粒体结构完好 ,B组可见线粒体肿胀 ,细胞膜不完整。C组、D组仅见少许线粒体肿胀 ,嵴少 ,与A组相近 ;心肌细胞A组有一定的凋亡 ,而B组凋亡数量明显上升 ,与A组相比有统计学意义 (P <0 .0 1) ,C组、D组凋亡数量无统计学意义 (P >0 .0 5 ) ,与B组相比明显下降 (P <0 .0 5 ) ,但仍比A组稍多 (P >0 .0 5 )。结论 :丹参注射液对心肌细胞缺糖缺氧 (缺血性 )损伤有较好的保护作用 ,其机制可能为降低损伤时细胞内酶的漏出 ,减轻心肌细胞缺血性损害超微结构及形态学的变化     

基质金属蛋白酶-9在哮喘大鼠气道重构中的作用及丹参干预的影响

目的探讨哮喘大鼠模型中基质金属蛋白酶-9（MMP-9）与气道重构的关系及丹参于预对气道重构的影响。方法重复雾化吸入卵蛋白8周建立大鼠哮喘气道重构模型。实验分为对照组,哮喘组,丹参干预组（每组8只大鼠）。免疫组化方法结合显微图像分析检测MMP-9表达。半定量PCR检测MMP-9mRNA水平。结果哮喘组动物出现管壁增厚．平滑肌增生．粘液分泌增加等气道重构的特征性改变．MMP-9 mRNA水平和蛋白表达明显增高。丹参组与哮喘组比较,炎症反应较轻微,平滑肌增生．粘液分泌不明显。MMP-9 mRNA水平和蛋白表达均降低．与对照组差异无显著性。结论少量多次变应原吸入可导致气道重构．MMP-9在气道重构中发挥作用,丹参干预可缓解气道重构的发生。     

Anti-TB polyynes from the roots of Angelica sinensis

Following chemotaxonomic evidence, the PE and CHCl(3) extracts of the roots of the botanical Angelica sinensis (Oliv.) Diels (Dang Gui) were investigated for in vitro anti-TB activity, in parallel to studying their serotonergic and GABAergic potential. The activities were confirmed to overlap chemically with the neurotropic active principles present in medium lipophilic fractions. Phytochemical investigations led to the isolation of five polyynes: falcarindiol (1), 9Z,17-octadecadiene-12,14-diyne-1,11,16-triol,1-acetate (2), oplopandiol (3), heptadeca-1-ene-9,10-epoxy-4,6-diyne-3,8-diol (4) and the new polyyne 8-hydroxy-1-methoxy-(Z)-9-heptadecene-4,6-diyn-3-one (5), as characterized by spectroscopic techniques including 1D, 2D NMR and HR-MS. All compounds were tested against two pathogenic strains of Mycobacterium tuberculosis (H37Rv and Erdman) in vitro in a microplate Alamar Blue assay (MABA). The most potent anti-TB constituents were 1 and 2, exhibiting MIC values of 1.4-26.7 microg/mL; 3 showed moderate MICs (49.5 and 50.2 microg/mL, respectively) while 4 and 5 were weakly active (MIC > 60 microg/mL). Notably, none of the five compounds exhibited significant cytotoxicity against Vero cells. These findings not only reveal a new potential area of therapeutic value for A. sinensis, but also underline the role of polyynes as anti-TB active principles in ethnobotanical preparations, and as lead compounds.     

杜元灏教授针刺治疗顽固性呃逆经验

杜元灏教授基于《灵枢》中呃逆的外治法，提出了“平抑胃气，调神止呃”的治疗原则，疗效显著。文章总结杜元灏教授治疗顽固性呃逆经验，并从神经解剖学和神经生理学角度进行了阐述，也借此探讨针灸治疗内脏疾病的思路。     

参附注射液对兔内毒素休克肺损伤的保护作用

用兔内毒素（ＥＴ）休克模型，对平均动脉压（ＭＡＰ）及支气管肺泡灌洗液（ＢＡＬＦ）中蛋白含量及吞噬细胞胞（ＰＡＭ）变化进行观测，探讨参附注射液（ＳＦ）对兔内毒素休克肺损伤的作用。结果：ＥＴ＋ＳＦ组ＭＡＰ虽下降，但２ｈ后开始上升，至６ｈ基本恢复正常，其与ＥＴ组比，Ｐ〈０．０５，与假手术组比，ＥＴ２ｈ后差异无显著性；对ＢＡＬＦ中细胞总数和ＰＭＮ，ＥＴ＋ＳＦ组与ＥＴ组比较，差异显著；蛋白定量，ＥＴ＋ＳＴ组     

补肾化瘀汤伍用雄激素治疗慢性再生障碍性贫血45例疗效分析

目的探讨中药补肾化瘀汤治疗慢性再生障碍性贫血（CAA）的疗效。方法88例CAA患者随机分为治疗组（用补肾化瘀汤治疗）和对照组（用西药治疗）,对两组不良反应和疗效进行l艋床观察。结果治疗组有效率93％,明显高于对照组。     

芪参胶囊治疗冠心病心绞痛临床研究

目的：探讨芪参胶囊治疗冠心病心绞痛的临床疗效、作用及特点。方法：212例在我院确诊为冠心病心绞痛的患者,口服芪参胶囊,3粒/次,3次/d。连服1个月。记录患者用药前、用药2周及1个月后症状和心电图变化,包括临床症状、血压、心率、舌象、脉象、心绞痛发作情况,检测用药前后肝肾功能、血常规、胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白。结果：芪参胶囊可明显缓解冠心病心绞痛患者的临床症状,降低心绞痛的发作频率和扩血管药物的含服率,无明显毒副作用。从中医辨证分型结果分析,芪参胶囊改善气虚血瘀型、心肾阳虚血瘀型患者的临床症状尤为明显,即对心肌梗死后合并心功能不全、冠状动脉旁路移植术后的阳虚患者疗效显著。结论：芪参胶囊能有效地防治冠心病心绞痛发作,提高患者的运动耐量,疗效确切,且更适用于治疗心肌梗死后合并心功能不全、冠状动脉旁路移植术后阳气虚弱,瘀血阻络的冠心病患者,是临床防治冠心病心肌梗死的有效复方中药制剂。     

黄参膏对胃癌癌前病变细胞凋亡及BCL-2蛋白表达的影响

目的:探讨黄参膏对胃癌癌前病变细胞凋亡及相关基因表达的影响。方法:将46例胃癌癌前病变患者随机分为2组,治疗组28例,口服黄参膏60ml/天,对照组18例,口服维酶素片2.4g/天,疗程2月,治疗前后检测细胞凋亡指数和Bcl-2蛋白的表达。采用原位末端标记法(TUNEL)检测细胞凋亡,采用免疫组化检测Bcl—2蛋白的表达。结果:黄参膏组服药前后细胞凋亡指数分别为19.8±9.6％和32.8±16.2％,服药后细胞凋亡指数显著高于服药前(P<0.05)。Bcl-2蛋白阳性率治疗前后分别为53.6％和28.6％,治疗前后比较具有显著性差异(P<0.05)。而对照组细胞凋亡指数和Bel-2蛋白阳性率在服药前后比较均无显著性差异(P>0.05)。结论:黄参膏可诱导胃癌癌前病变细胞凋亡。     

Dang Shen [Codonopsis pilosula (Franch.) Nannf] Herbal Formulae for Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta‐analysis

This systematic review and meta‐analysis assessed the efficacy and safety of Dang shen [Codonopsis pilosula (Franch.) Nannf., root] formulae for the treatment of chronic obstructive pulmonary disease (COPD). English and Chinese databases were searched, and 48 randomized controlled trials were included. Dang shen formulae improved lung function forced expiratory volume in 1 s compared with conventional pharmacotherapy (CP) [mean difference (MD) 0.22 L, 95% confidence interval (CI) 0.13–0.31, p < 0.001, I² = 5%] and quality of life (St. Georges Respiratory Questionnaire) compared with placebo (MD ?7.19, 95% CI ?10.82 to ?3.56, p < 0.001, I² = 0%) and when combined with CP versus CP (MD ?9.05, 95% CI ?12.72 to ?5.38, p < 0.001, I² = 89%). Dang shen formulae also increased distance walked in 6 min when combined with CP versus CP alone (MD 51.43 m, 95% CI 30.06–72.80, p < 0.001, I² = 27%) and reduced frequency/days with COPD exacerbations. Risk of bias was evaluated using the Cochrane tool. Methodological shortfalls were identified. Adverse events were low and not different between intervention and control groups. Thirty‐three events were reported, including gastrointestinal upset, dry mouth, and insomnia. Dang shen formulae appear to improve some aspects of the included COPD outcomes. However, owing to methodological flaws, the current evidence is inadequate to support the routine use of Dang shen formulae outside of Chinese medicine practice. However, these results justify further investigation. Copyright © 2014 John Wiley & Sons, Ltd.     

泰山四叶参新品种“泰参2号”的选育

目的：选育适宜加工的四叶参新品种。方法：以四叶参野生与农家种质资源为亲本材料,采用集团混合选择育种方法。结果：育成品种“泰参2号”茎秆绿紫色、粗壮;叶片卵形;地下根圆柱形或纺锤形,根体长、根粗、单根重、高产、根少分枝。新品种示范产量每公顷9234．45kg,比对照品种泰参1号平均增产14．69％。结论：“泰参2号”为四叶参开发、加工利用提供了专用品种。